Suspected statin-induced respiratory muscle myopathy during long-term inspiratory muscle training in a patient with diaphragmatic paralysis

Physical Therapy

Volumn 89, Issue 3, 2009, Pages 257-266

  Chatham, Ken ^a   Gelder, Colin M ^a   Lines, Thomas A ^a   Cahalin, Lawrence P ^b  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; SIMVASTATIN;

ADULT; ARTICLE; BRACHIAL PLEXUS NEUROPATHY; BREATHING EXERCISE; BREATHING MUSCLE; CASE REPORT; CERVICAL SPONDYLOSIS; DAILY LIFE ACTIVITY; DIAPHRAGM PARALYSIS; DRUG WITHDRAWAL; DYSPNEA; ENDURANCE; FUNCTIONAL ASSESSMENT; HUMAN; HYPERLIPIDEMIA; INSPIRATORY MUSCLE TRAINING; LONG TERM CARE; LUNG FUNCTION; MALE; MUSCLE STRENGTH; MYOPATHY; NECK INJURY; PHYSIOTHERAPY; SPORT INJURY; TRAINING; TREATMENT OUTCOME;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PHYSICAL EXAMINATION; RESISTANCE TRAINING; RESPIRATORY MUSCLES; RESPIRATORY PARALYSIS;

EID: 61849172443     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.2522/ptj.20080155     Document Type: Article

References (35)

1. Castelli WP. Lipids, risk factors, and ischemic heart disease. Athersclerosis. 1996;124:S1S9.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285; 2486-2497.
3. Pasternak RC, Smith SC Jr, Balrey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 2003;106:1024-1028.
4. Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163:688-692.
5. Jackevicius CA, Ross JS, Ko DT, Kramholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358:110.
6. Johnson LA. Congress-Vytorin makers held bad news. Associated Press. Available at: http://www.wtopnews.com/?nid=111&sid=1333328. Accessed April 1, 2008.
7. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291:1208-1212.
8. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systemic review. J Am Coll Cardiol. 2007;49:2231-2237.
9. Marie I, Delafenêtre H, Massy N, et al; Network of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study of ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum. 2008;59:367-372.
10. Laaksonen R, Katajamaa M, Päivä H, et al. A systems biology strategy reveals biological pathway and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE. 2006;l(l):e97.
11. Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/ MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007; 117:3940-3951.
12. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:15.
13. Phillips O, Haas R, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002; 138:581-585.
14. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30:799-802.
15. Tufan A, Dede DS, Cavus S, et al. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40:1466-1469.
16. Francis L, Bonilla E, Soforo E, et al. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol. 2008;27: 129-131.
17. Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85:459-465.
18. West JB. Pulmonary Pathophysiology: The Essentials. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
19. Part two: preferred practice patterns. In: Guide to Physical Therapist Practice. 2nd ed. Phys Ther. 2001;81:139-681.
20. Ionescu AA, Nixon LS, Evans WD, et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med. 2000; 162(3 pt l):789-794.
21. Mickleborough TD, Nichols T, Chatham K, et al. The effect of high- and low-intensity inspiratory muscle training on the physiological response to exercise in recreational runners [abstract]. Am J Respir Crit Care Med. 2003;167:A541.
22. Chatham K, Ionescu AA, Nixon LS, Shale DJ. A short-term comparison of two methods of sputum expectoration in cystic fibrosis. Eur Respir J. 2004;23:435-439.
23. Chatham K, Baldwin J, Griffiths H, et al. Inspiratory muscle training improves shuttle run performance in healthy subjects. Physiotherapy. 1999,85:676-683.
24. Enright SJ, Chatham K, Ionescu AA, et al. Inspiratory muscle training improves lung function and exercise capacity in adults with cystic fibrosis. Chest. 2004;126:405-411.
25. Enright SJ, Unnithan VB, Heward C, et al. Effect of high-intensity inspiratory muscle training on lung volumes, diaphragm thickness, and exercise capacity in subjects who are healthy. Phys Ther. 2006;86:345-354.
26. Bruton A. A pilot study to investigate any relationship between sustained maximal inspiratory pressure and extubation outcome. Heart Lung. 2002;31:141-149.
27. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis. 1969;99:696-702.
28. Gething AD, Williams M, Davies B. Inspiratory resistive loading improves cycling capacity: a placebo controlled trial. Br J Sports Med. 2004;38:730-736
29. Reid WD, Crowe J, OBrien K, Brooks D. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: a systematic review. Respir Med. 2005;99:1440-1458.
30. Lotters F, van Tol B, Kwakkel G, Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD. a meta-analysis. Eur Respir J. 2002;20:570-576.
31. Cahalin LP, Semigran MJ, Dec GW. Inspiratory muscle training in patients with chronic heart failure awaiting cardiac transplantation: results of a pilot clinical trial. Phys Ther. 1997;77:830-838.
32. Weiner P, Azgad Y, Weiner M. The effect of corticosteriods on inspiratory muscle performance in humans. Chest. 1993;104:1788-1791.
33. Weiner P, Azgad Y, Weiner M. Inspiratory muscle training during treatment with corticosteroids in humans. Chest. 1995;107:1041-1044.
34. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996;348:1079-1082.
35. Witt JD, Guenette JA, Rupert JL, et al. Inspiratory muscle training attenuates the human respiratory muscle metaboreflex. J Physiol. 2007;584:1019-1028.